Moderna (MRNA) Cash from Operations Growth (5y) (2023 - 2026)
Moderna (MRNA) Cash from Operations Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Moderna | 21.88 Bn | 16.67 Bn | -566.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.21% |
| Dec 31, 2025 | -5.95% |
| Sep 30, 2025 | -24.14% |
| Jun 30, 2025 | -107.31% |
| Mar 31, 2025 | -57.80% |
| Dec 31, 2024 | 59.52% |
| Sep 30, 2024 | -71.00% |
| Jun 30, 2024 | -63.64% |
| Mar 31, 2024 | -46.96% |
| Dec 31, 2023 | 54.61% |
| Sep 30, 2023 | -81.96% |
| Jun 30, 2023 | -80.13% |
| Mar 31, 2023 | -61.53% |